Metastasectomy for Recurrent or Metastatic Biliary Tract Cancers: A Single Center Experience
Soonchunhyang Medical Science
; : 1-7, 2016.
Article
Dans En
| WPRIM
| ID: wpr-83516
Responsable en Bibliothèque :
WPRO
ABSTRACT
OBJECTIVE:
Efficacy or long-term result of metastasectomy for recurrent or metastatic biliary tract carcinoma (BTC) is not well established. We conducted a retrospective review of the outcomes of metastasectomy for recurrent or metastatic BTCs.METHODS:
The clinicopathological features and outcomes of consecutive patients with BTCs who underwent surgical resection for primary and metastatic disease at a tertiary referral hospital from 2003 to 2013 were reviewed retrospectively.RESULTS:
We found 19 eligible patients. Median age of patients was 57 years old (range, 27 to 68 years old), and 11 patients (58%) were female. Primary sites were gallbladder cancer (seven patients, 37%), intrahepatic cholangiocarcinoma (five patients, 26%), distal common bile duct cancer (three patients, 16%), proximal common bile duct cancer (two patients, 11%), and ampulla of Vater cancer (two patients, 11%). Eight patients (42%) had synchronous metastasis, while 11 (58%) had metachronous metastasis. The most common metastatic site was liver (nine patients, 47%), lymph node (nine patients, 47%), and peritoneum (three patients, 16%). Nine patients (47%) achieved R0 resection, while four (21%) and six (32%) patients had R1 and R2 resection, respectively. With a median follow-up period of 26.7 months, the estimated median overall survival (OS) was 18.2 months (95% confidence interval [CI], 13.6 to 22.9 months). Lower Eastern Cooperative Oncology Group performance status (P=0.023), metachronous metastasis (P=0.04), absence of lymph node metastasis (P=0.009), lower numbers of metastatic organs (P<0.001), normal postoperative carbohydrate antigen 19-9 level (P=0.034), and time from diagnosis to metastasectomy more than one year (P=0.019) were identified as prognostic factors for a longer OS after metastasectomy.CONCLUSION:
For recurrent or metastatic BTCs, metastasectomy can be a viable option for selected patients.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Péritoine
/
Pronostic
/
Ampoule hépatopancréatique
/
Voies biliaires
/
Tumeurs des voies biliaires
/
Études rétrospectives
/
Études de suivi
/
Cholangiocarcinome
/
Conduit cholédoque
/
Diagnostic
Type d'étude:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Limites du sujet:
Female
/
Humans
langue:
En
Texte intégral:
Soonchunhyang Medical Science
Année:
2016
Type:
Article